ImadGist
This is a 2 arms study concerning patients with primary GIST who followed an Imatinib
adjuvant treatment for 3 years after surgery and who have a high risk of recurrence. In the first arm, patients will continue Imatinib treatment for 3 more years, allowing to
determine if the continuation of this treatment is efficient for disease control, in terms of
Disease Free Survival improvement. In the second arm, patients will discontinue the Imatinib treatment, as standard practice.
This arm will allow to determine if the re-introduction of Imatinib at relapse is still an
efficient treatment for the control of disease.
Dec 24,2014
All
18 Years
N/A
18 Years
N/A
134